Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics

World Journal of Gastroenterology

Volumn 21, Issue 1, 2015, Pages 60-83

  Gatselis, Nikolaos K ^a   Zachou, Kalliopi ^a   Koukoulis, George K ^a   Dalekos, George N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Autoimmune hepatitis; Liver autoimmunity; Liver related autoantibodies; Non organ specific autoantibodies; Overlap syndromes

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; AUTOANTIBODY; CORTICOSTEROID; DICLOFENAC; GAMMA INTERFERON; METHYLDOPA; ORNIDAZOLE; OXYPHENISATINE; BIOLOGICAL MARKER;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; EMPERIPOLESIS; ETHNIC GROUP; HISTOPATHOLOGY; HUMAN; HYPERGAMMAGLOBULINEMIA; LIVER HISTOLOGY; LIVER INJURY; MOLECULAR MIMICRY; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; SEROLOGY; SEX DIFFERENCE; ANIMAL; BLOOD; CLASSIFICATION; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; LIVER; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ANIMALS; AUTOANTIBODIES; BIOMARKERS; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; PHENOTYPE; PROGNOSIS; RISK FACTORS;

EID: 84920897099     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i1.60     Document Type: Article

References (254)

1. Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, Dalekos GN, Muratori L. Review article: autoimmune hepatitis - current management and challenges. Aliment Pharmacol Ther 2013; 38: 887-913 [PMID: 24010812 DOI: 10.1111/apt.12470]
2. Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 2002; 13: 293-303 [PMID: 12144908 DOI: 10.1016/S0953-6205(02)00089-4]
3. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem 2005; 40: 127-164 [PMID: 16355922 DOI: 10.1016/ S0065-2423(05)40004-9]
4. Krawitt EL . Can you recognize autoimmune hepatitis? Postgrad Med 1998; 104: 145-149, 152 [PMID: 9721584]
5. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005 [PMID: 8406375 DOI: 10.1002/hep.1840180435]
6. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938 [PMID: 10580593 DOI: 10.1016/S0168-8278(99)80297-9]
7. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176 [PMID: 18537184 DOI: 10.1002/hep.22322]
8. Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 2004; 1: 2 [PMID: 15679907 DOI: 10.1186/1740-2557-1-2]
9. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23584]
10. Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-1629 [PMID: 21757447 DOI: 10.1136/gut.2010.235259]
11. Bogdanos DP, Dalekos GN. Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450s. Curr Med Chem 2008; 15: 2285-2292 [PMID: 18781950 DOI: 10.2174/092986708785747508]
12. Mieli-Vergani G, Heller S, Jara P, Vergani D, Chang MH, Fujisawa T, González-Peralta RP, Kelly D, Mohan N, Shah U, Murray KF. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009; 49: 158-164 [PMID: 19561543 DOI: 10.1097/MPG.0b013e3181a1c265]
13. Vergani D, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP, Nishioka M, Penner E. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683 [PMID: 15464251 DOI: 10.1016/j.jhep.2004.08.002]
14. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Lévy VG, Grippon P. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333-1339 [PMID: 3679093 DOI: 10.1002/hep.1840070626]
15. Fabien N, Desbos A, Bienvenu J, Magdalou J. Autoantibodies directed against the UDP-glucuronosyltransferases in human autoimmune hepatitis. Autoimmun Rev 2004; 3: 1-9 [PMID: 14871643 DOI: 10.1016/S1568-9972(03)00051-X]
16. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 1662-1666 [PMID: 3192182 DOI: 10.1002/hep.1840080632]
17. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013; 41: 126-139 [PMID: 23218932 DOI: 10.1016/j.jaut.2012.11.002]
18. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99-103 [PMID: 9489916 DOI: 10.1080/00365529850166284]
19. Berdal JE, Ebbesen J, Rydning A. [Incidence and prevalence of autoimmune liver diseases]. Tidsskr Nor Laegeforen 1998; 118: 4517-4519 [PMID: 9889636]
20. Boberg KM . Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002; 6: 635-647 [PMID: 12362572 DOI: 10.1016/S1089-3261(02)00021-1]
21. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol 2003; 18: 1118-1128 [PMID: 12974897 DOI: 10.1046/j.1440-1746.2003.03165.x]
22. Werner M, Prytz H, Ohlsson B, Almer S, Björnsson E, Bergquist A, Wallerstedt S, Sandberg-Gertzén H, Hultcrantz R, Sangfelt P, Weiland O, Danielsson A. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1232-1240 [PMID: 18609163 DOI: 10.1080/00365520802130183]
23. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002; 97: 2402-2407 [PMID: 12358264 DOI: 10.1111/j.1572-0241.2002.06019.x]
24. Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, Stedman CA. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010; 25: 1681-1686 [PMID: 20880179 DOI: 10.1111/j.1440-1746.2010.06384.x]
25. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 2001; 96: 3390-3394 [PMID: 11774954 DOI: 10.1111/j.1572-0241.2001.05272.x]
26. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol 2012; 46: 155-161 [PMID: 21814143 DOI: 10.1097/MCG.0b013e318228b781]
27. Muratori L, Longhi MS. The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies. J Autoimmun 2013; 46: 74-80 [PMID: 23871639 DOI: 10.1016/j.jaut.2013.06.016]
28. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47: 2139-2150 [PMID: 12395884]
29. Muratori P, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F, Granito A, Ferrari R, Mantovani V, Lenzi M, Bianchi FB. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol 2005; 11: 1862-1866 [PMID: 15793882]
30. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174: 250-259 [PMID: 10807521 DOI: 10.1034/j.1600-0528.2002.017401.x]
31. Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, Daruich J, Findor J, Tanno H, Cañero-Velasco C, Fainboim L. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999; 30: 1374-1380 [PMID: 10573514 DOI: 10.1016/j.jhep.2007.08.019]
32. Czaja AJ, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC, Donaldson PT. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002; 37: 302-308 [PMID: 12175624 DOI: 10.1016/S0168-8278(02)00182-4]
33. de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Kraal G, Mulder CJ, van Nieuwkerk CM, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse AW, Weiler-Normann C, Lerch MM, Nauck M, Völzke H, Homuth G, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014; 147: 443-452.e5 [PMID: 24768677 DOI: 10.1053/j.gastro.2014.04.022]
34. Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130: 868-882 [PMID: 16530525 DOI: 10.1053/j.gastro.2005.12.020]
35. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000; 31: 49-53 [PMID: 10613727 DOI: 10.1002/ hep.510310110]
36. Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999; 30: 851-856 [PMID: 10498633 DOI: 10.1002/hep.510300412]
37. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 2007; 69: 227-235 [PMID: 17493146 DOI: 10.1111/ j.1399-0039.2006.00794.x]
38. Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y, Muratori L, Tsantoulas D, Mieli- Vergani G, Bianchi FB, Vergani D. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004; 17: 83-92 [PMID: 15000871]
39. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989; 83: 1066-1072 [PMID: 2466049]
40. Gueguen M, Yamamoto AM, Bernard O, Alvarez F. Anti-liver-kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochem Biophys Res Commun 1989; 159: 542-547 [PMID: 2930529 DOI: 10.1016/0006-291X(89)90027-2]
41. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 85: 8256-8260 [PMID: 3186722]
42. Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 1481-1489 [PMID: 12538711 DOI: 10.4049/jimmunol.170.3.1481]
43. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370-1378 [PMID: 1717511 DOI: 10.1172/JCI115443]
44. Manns MP, Jentzsch M, Mergener K. Discordant manifestation of LKM-1 antibody positive autoimmune hepatitis in identical twins. Hepatology 1990; 12: 840 [abstract]
45. Ma Y, Thomas MG, Okamoto M, Bogdanos DP, Nagl S, Kerkar N, Lopes AR, Muratori L, Lenzi M, Bianchi FB, Mieli-Vergani G, Vergani D. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol 2002; 169: 277-285 [PMID: 12077255 DOI: 10.4049/jimmunol.169.1.277]
46. Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G, Carini R, Lenzi M, Landini MP, Albano E, Bianchi FB. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000; 46: 553-561 [PMID: 10716687 DOI: 10.1136/gut.46.4.553]
47. Loeper J, Louérat-Oriou B, Duport C, Pompon D. Yeast expressed cytochrome P450 2D6 (CYP2D6) exposed on the external face of plasma membrane is functionally competent. Mol Pharmacol 1998; 54: 8-13 [PMID: 9658184 DOI: 10.1124/mol.54.1.8]
48. Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10: 744-755 [PMID: 21621000 DOI: 10.1016/j.autrev.2011.05.004]
49. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004; 41: 31-37 [PMID: 15246204 DOI:10.1016/ j.jhep.2004.03.008]
50. Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, Ma Y. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176: 4484-4491 [PMID: 16547287 DOI: 10.4049/ jimmunol.176.7.4484]
51. Peiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse AW, Weiler-Normann C, Schramm C, Herkel J. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 2012; 57: 125-132 [PMID: 22425700 DOI: 10.1016/j.jhep.2012.02.029]
52. Taubert R, Hardtke-Wolenski M, Noyan F, Wilms A, Baumann AK, Schlue J, Olek S, Falk CS, Manns MP, Jaeckel E. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol 2014; 61: 1106-1114 [PMID: 24882050 DOI: 10.1016/j.transproceed.2013.01.073]
53. Sebode M, Peiseler M, Weiler-Normann C, Schramm C, Lohse AW, Herkel J. Phenotypic alterations of regulatory T cells in autoimmune hepatitis: causal or associated with treatment and remission? Hepatology 2014; Epub ahead of print [PMID: 25044332 DOI: 10.1002/hep.27301]
54. Zingaretti C, Arigò M, Cardaci A, Moro M, Crosti M, Sinisi A, Sugliano E, Cheroni C, Marabita F, Nogarotto R, Bonnal RJ, Marcatili P, Marconi M, Zignego A, Muratori P, Invernizzi P, Colombatto P, Brunetto M, Bonino F, De Francesco R, Geginat J, Pagani M, Muratori L, Abrignani S, Bombaci M. Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. Mol Cell Proteomics 2012; 11: 1885-1897 [PMID: 22997428 DOI: 10.1074/mcp.M112.018713]
55. Lohse AW, Manns M, Dienes HP, Meyer zum Büschenfelde KH, Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 1990; 11: 24-30 [PMID: 2271015 DOI: 10.1002/hep.1840110106]
56. Voehringer D, Blaser C, Grawitz AB, Chisari FV, Buerki K, Pircher H. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J Immunol 2000; 165: 2415-2422 [PMID: 10946266 DOI: 10.4049/jimmunol.165.5.2415]
57. Djilali-Saiah I, Lapierre P, Vittozi S, Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J Immunol 2002; 169: 4889-4896 [PMID: 12391200 DOI: 10.4049/jimmunol.169.9.4889]
58. Derkow K, Loddenkemper C, Mintern J, Kruse N, Klugewitz K, Berg T, Wiedenmann B, Ploegh HL, Schott E. Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology 2007; 46: 1155-1165 [PMID: 17657820 DOI: 10.1002/hep.21796]
59. Zierden M, Kühnen E, Odenthal M, Dienes HP. Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis. Gastroenterology 2010; 139: 975-986, 986.e1-3 [PMID: 20639127 DOI: 10.1053/j.gastro.2010.05.075]
60. Hintermann E, Ehser J, Christen U. The CYP2D6 animal model: how to induce autoimmune hepatitis in mice. J Vis Exp 2012; (60): 3644 [PMID: 22331063 DOI: 10.3791/3644]
61. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004; 39: 1066-1074 [PMID: 15057911 DOI: 10.1002/hep.20109]
62. Lapierre P, Béland K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun 2006; 26: 82-89 [PMID: 16380229 DOI: 10.1016/j.jaut.2005.11.001]
63. Lapierre P, Béland K, Martin C, Alvarez F, Alvarez F. Forkhead box p3+ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology 2010; 51: 1789-1798 [PMID: 20232291 DOI: 10.1002/hep.23536]
64. Lapierre P, Béland K, Yang R, Alvarez F. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 2013; 57: 217-227 [PMID: 22911361 DOI: 10.1002/hep.26023]
65. Ehser J, Holdener M, Christen S, Bayer M, Pfeilschifter JM, Hintermann E, Bogdanos D, Christen U. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmun 2013; 42: 39-49 [PMID: 23200317 DOI: 10.1016/j.jaut.2012.11.001]
66. Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, Johnson EF, Gonzalez FJ, Pfeilschifter J, Manns MP, Herrath Mv, Christen U. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008; 205: 1409-1422 [PMID: 18474629 DOI: 10.1084/jem.20071859]
67. Iwamoto S, Kido M, Aoki N, Nishiura H, Maruoka R, Ikeda A, Okazaki T, Chiba T, Watanabe N. TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol 2013; 146: 15-25 [PMID: 23178752 DOI: 10.1016/j.clim.2012.10.008]
68. Kido M, Watanabe N, Okazaki T, Akamatsu T, Tanaka J, Saga K, Nishio A, Honjo T, Chiba T. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008; 135: 1333-1343 [PMID: 18651994]
69. Aoki N, Kido M, Iwamoto S, Nishiura H, Maruoka R, Tanaka J, Watanabe T, Tanaka Y, Okazaki T, Chiba T, Watanabe N. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastroenterology 2011; 140: 1322-1333.e1-5 [PMID: 21237169 DOI: 10.1053/j.gastro.2011.01.002]
70. Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011; 46: 1136-1141 [PMID: 21597932 DOI: 10.1007/s00535-011-0421-y]
71. Muratori P, Granito A, Quarneti C, Ferri S, Menichella R, Cassani F, Pappas G, Bianchi FB, Lenzi M, Muratori L. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009; 50: 1210-1218 [PMID: 19395113 DOI: 10.1016/j.jhep.2009.01.020]
72. Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006; 24: 519-523 [PMID: 16886918]
73. Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, Baldo V, Premoli A, Olivero F, Morello E, Durazzo M. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006; 24: 1051-1057 [PMID: 16984499 DOI: 10.1111/j.1365-2036.2006.03104.x]
74. Schramm C, Kanzler S, zum Büschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001; 96: 1587-1591 [PMID: 11374704 DOI: 10.1111/j.1572-0241.2001.03782.x]
75. Peng M, Li Y, Zhang M, Jiang Y, Xu Y, Tian Y, Peng F, Gong G. Clinical features in different age groups of patients with autoimmune hepatitis. Exp Ther Med 2014; 7: 145-148 [PMID: 24348780 DOI: 10.3892/etm.2013.1363]
76. Gronbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60: 612-617 [PMID: 24326217 DOI: 10.1016/ j.jhep.2013.10.020]
77. Chen J, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther 2014; 39: 117-124 [PMID: 24261965 DOI: 10.1111/apt.12563]
78. Granito A, Muratori L, Pappas G, Muratori P, Ferri S, Cassani F, Lenzi M, Bianchi FB. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005; 21: 1273-1277 [PMID: 15882249 DOI: 10.1111/j.1365-2036.2005.02488.x]
79. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45: 575-583 [PMID: 16899323 DOI: 10.1016/j.jhep.2006.04.007]
80. Stravitz RT, Lefkowitch JH, Fontana RJ, Gershwin ME, Leung PS, Sterling RK, Manns MP, Norman GL, Lee WM. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011; 53: 517-526 [PMID: 21274872 DOI: 10.1002/hep.24080]
81. Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: Does it exist? A published work review. Hepatol Res 2011; 41: 498-504 [PMID: 21595804 DOI: 10.1111/j.1872-034X.2011.00808.x]
82. Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, Verucchi G, Cassani F, Chiodo F, Bianchi FB. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM 2004; 97: 407-412 [PMID: 15208428 DOI: 10.1093/qjmed/hch072]
83. Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, Sakaguchi K, Shiratori Y. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006; 23: 1347-1353 [PMID: 16629940 DOI: 10.1111/j.1365-2036.2006.02894.x]
84. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62 [PMID: 15954109 DOI: 10.1002/hep.20732]
85. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011; 55: 636-646 [PMID: 21238519 DOI: 10.1016/j.jhep.2010.12.032]
86. Landeira G, Morise S, Fassio E, Ramonet M, Alvarez E, Caglio P, Longo C, Domínguez N. Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis. Ann Hepatol 2012; 11: 100-106 [PMID: 22166568]
87. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185 [PMID: 4933363]
88. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitniæk GL, Elveback IR, Schoenfield LJ. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833 [PMID: 4538724]
89. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-737 [PMID: 4121073]
90. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002; 35: 75-81 [PMID: 12080231]
91. Brissos J, Carrusca C, Correia M, Cabral J. Autoimmune hepatitis: trust in transaminases. BMJ Case Rep 2014; 2014: [PMID: 24759606 DOI: 10.1136/bcr-2014-203869]
92. Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002; 97: 3160-3165 [PMID: 12492204 DOI: 10.1111/j.1572-0241.2002.07124.x]
93. Samuel D, Riordan S, Strasser S, Kurtovic J, Singh-Grewel I, Koorey D. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol 2004; 2: 622-624 [PMID: 15224286 DOI: 10.1016/S1542-3565(04)00245-9]
94. Efe C, Purnak T, Ozaslan E. Autoimmune hepatitis in the postpartum period. Clin Res Hepatol Gastroenterol 2012; 36: 391-393 [PMID: 22481086 DOI: 10.1016/j.clinre.2012.02.006]
95. Westbrook RH, Yeoman AD, Kriese S, Heneghan MA. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun 2012; 38: J239-J244 [PMID: 22261501 DOI: 10.1016/j.jaut.2011.12.002]
96. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102 [PMID: 11115829 DOI: 10.1136/gut.48.1.97]
97. McFarlane IG, Heneghan MA. Autoimmunity and the female liver. Hepatol Res 2004; 28: 171-176 [PMID: 15040956 DOI: 10.1016/j.hepres.2003.12.002]
98. Castiella A, Zapata E, Lucena MI, Andrade RJ. Druginduced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J Hepatol 2014; 6: 160-168 [PMID: 24799984 DOI: 10.4254/wjh.v6.i4.160]
99. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP, Homberg JC. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551-555 [PMID: 3540968]
100. Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, Guengerich FP, Beaune PH. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazineinduced hepatitis. J Clin Invest 1990; 85: 1967-1973 [PMID: 2347920 DOI: 10.1172/JCI114660]
101. Obermayer-Straub P, Perheentupa J, Braun S, Kayser A, Barut A, Loges S, Harms A, Dalekos G, Strassburg CP, Manns MP. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology 2001; 121: 668-677 [PMID: 11522751 DOI: 10.1053/gast.2001.27103]
102. Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Rep 2010; 4: 311 [PMID: 20863377 DOI: 10.1186/1752-1947-4-311]
103. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K. Druginduced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-2048 [PMID: 20512992 DOI: 10.1002/hep.23588]
104. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Lucena MI, Castiella A, Lindor K, Björnsson E. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54: 931-939 [PMID: 21674554 DOI: 10.1002/hep.24481]
105. Lisotti A, Azzaroli F, Brillanti S, Mazzella G. Severe acute autoimmune hepatitis after natalizumab treatment. Dig Liver Dis 2012; 44: 356-357 [PMID: 22154948 DOI: 10.1016/j.dld.2011.11.003]
106. Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol 2012; 68: 895-898 [PMID: 22205272 DOI: 10.1007/s00228-011-1191-4]
107. van Casteren-Messidoro C, Prins G, van Tilburg A, Zelinkova Z, Schouten J, de Man R. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis 2012; 6: 630-631 [PMID: 22398075 DOI: 10.1016/j.crohns.2012.01.017]
108. 'Leary JG, Zachary K, Misdraji J, Chung RT. De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clin Infect Dis 2008; 46: e12-e14 [PMID: 18171203 DOI: 10.1086/524082]
109. Saitis A, Gatselis N, Zachou K, Dalekos GN. Use of TNFα antagonists in refractory AIH: revealing the unforeseen. J Hepatol 2013; 59: 197-198 [PMID: 23528379 DOI: 10.1016/j.jhep.2013.02.029]
110. Borman MA, Urbanski S, Swain MG. Anti-TNF-induced autoimmune hepatitis. J Hepatol 2014; 61: 169-170 [PMID: 24636834 DOI: 10.1016/j.jhep.2014.01.032]
111. Kern E, VanWagner LB, Yang GY, Rinella ME. Liraglutideinduced autoimmune hepatitis. JAMA Intern Med 2014; 174: 984-987 [PMID: 24733687 DOI: 10.1001/jamainternmed.2014.674]
112. Vento S, Guella L, Mirandola F, Cainelli F, Di Perri G, Solbiati M, Ferraro T, Concia E. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995; 346: 608-609 [PMID: 7651006 DOI: 10.1016/S0140-6736(95)91438-2]
113. Cabibi D . Autoimmune hepatitis following Epstein-Barr virus infection. BMJ Case Rep 2008; 2008: bcr0620080071 [PMID: 21716814 DOI: 10.1136/bcr.06.2008.0071]
114. Zellos A, Spoulou V, Roma-Giannikou E, Karentzou O, Dalekos GN, Theodoridou M. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? Ann Hepatol 2013; 12: 147-151 [PMID: 23293207]
115. Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H, Manns MP. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999; 30: 366-375 [PMID: 10190716 DOI: 10.1016/ S0168-8278(99)80092-0]
116. Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, Zauli D, Bianchi FB. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21: 199-203 [PMID: 7989709 DOI: 10.1016/S0168-8278(05)80395-2]
117. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, Verme G, Rizzetto M. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22: 1374-1378 [PMID: 7590650 DOI: 10.1002/hep.1840220506]
118. Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, Dhillon A. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006; 81: 488-490 [PMID: 16477242 DOI: 10.1097/01.tp.0000196716.07188.c4]
119. Vento S, Cainelli F, Renzini C, Concia E. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997; 350: 1298-1299 [PMID: 9357416 DOI: 10.1016/S0140-6736(05)62476-2]
120. Kerkar N, Hadziæ N, Davies ET, Portmann B, Donaldson PT, Rela M, Heaton ND, Vergani D, Mieli-Vergani G. Denovo autoimmune hepatitis after liver transplantation. Lancet 1998; 351: 409-413 [PMID: 9482295 DOI: 10.1016/ S0140-6736(97)06478-7]
121. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004; 40: 3-7 [PMID: 14672607 DOI: 10.1016/j.jhep.2003.10.022]
122. Fiel MI, Schiano TD. Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. Curr Opin Organ Transplant 2012; 17: 287-292 [PMID: 22498651 DOI: 10.1097/MOT.0b013e3283536622]
123. Rigopoulou EI, Dalekos G, Bogdanos DP. How common are connective tissue disorders in patients with autoimmune hepatitis? Semin Arthritis Rheum 2007; 36: 332; author reply 333 [PMID: 17276497 DOI: 10.1016/j.semarthrit.2006.11.005]
124. Stefanidis I, Giannopoulou M, Liakopoulos V, Dovas S, Karasavvidou F, Zachou K, Koukoulis GK, Dalekos GN. A case of membranous nephropathy associated with Sjögren syndrome, polymyositis and autoimmune hepatitis. Clin Nephrol 2008; 70: 245-250 [PMID: 18793567]
125. Gatselis NK, Zachou K, Norman GL, Tzellas G, Speletas M, Gabeta S, Germenis A, Koukoulis GK, Dalekos GN. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clin Chim Acta 2012; 413: 1683-1688 [PMID: 22643316 DOI: 10.1016/j.cca.2012.05.015]
126. Fujii K, Rokutanda R, Osugi Y, Koyama Y, Ota T. Adult-onset Still's disease complicated by autoimmune hepatitis: successful treatment with infliximab. Intern Med 2012; 51: 1125-1128 [PMID: 22576401 DOI: 10.2169/internalmedicine.51.6824]
127. Panetta F, Nobili V, Sartorelli MR, Papa RE, Ferretti F, Alterio A, Diamanti A. Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management. Paediatr Drugs 2012; 14: 35-41 [PMID: 22149550 DOI: 10.2165/11593150-000000000-00000]
128. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune polyglandular syndrome type 1. Clin Rev Allergy Immunol 2000; 18: 167-183 [PMID: 10944704]
129. Finnish-German APECED Consortium . An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17: 399-403 [PMID: 9398840 DOI: 10.1038/ng1297-399]
130. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJ, Lalioti MD, Mullis PE, Antonarakis SE, Kawasaki K, Asakawa S, Ito F, Shimizu N. Positional cloning of the APECED gene. Nat Genet 1997; 17: 393-398 [PMID: 9398839 DOI: 10.1038/ng1297-393]
131. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasisectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829-1836 [PMID: 2348835 DOI: 10.1056/NEJM199006283222601]
132. Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology 2001; 33: 1047-1052 [PMID: 11343230]
133. Papamichalis PA, Zachou K, Koukoulis GK, Veloni A, Karacosta EG, Kypri L, Mamaloudis I, Gabeta S, Rigopoulou EI, Lohse AW, Dalekos GN. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis 2007; 4: 3 [PMID: 17603886 DOI: 10.1186/1740-2557-4-3]
134. Georgiadou SP, Zachou K, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 2009; 29: 434-442 [PMID: 18694399 DOI: 10.1111/j.1478-3231.2008.01851.x]
135. Gatselis NK, Zachou K, Papamichalis P, Koukoulis GK, Gabeta S, Dalekos GN, Rigopoulou EI. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? Dig Liver Dis 2010; 42: 807-812 [PMID: 20399157 DOI: 10.1016/j.dld.2010.03.005]
136. Azhar A, Niazi MA, Tufail K, Malek AH, Balasubramanian M, Araya V. A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome. Gastroenterol Hepatol (N Y) 2010; 6: 233-236 [PMID: 20567575]
137. Rigopoulou EI, Zachou K, Gatselis N, Koukoulis GK, Dalekos GN. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Ann Hepatol 2013; 13: 127-135 [PMID: 24378276]
138. Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009; 15: 578-582 [PMID: 19195059 DOI: 10.3748/wjg.15.578]
139. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, Bomford A, O'Grady JG, Harrison PM, Heneghan MA. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008; 48: 863-870 [PMID: 18752332 DOI: 10.1002/hep.22432]
140. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55: 522-529 [PMID: 21994151 DOI: 10.1002/ hep.24743]
141. Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, Ohta H, Shimada M, Mita E, Hijioka T, Yamashita H, Takezaki E, Muro T, Sakai H, Nakamuta M, Abiru S, Komori A, Ito M, Yatsuhashi H, Nakamura M, Ishibashi H. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int 2012; 32: 837-844 [PMID: 22221966 DOI: 10.1111/ j.1478-3231.2011.02734.x]
142. Yamamoto K, Hiura M, Tabaru A, Honma Y, Narita R, Abe S, Shimajiri S, Okamoto K, Yamaguchi K, Harada M. Rapid progression of hepatocellular carcinoma in a patient with autoimmune hepatitis. Intern Med 2011; 50: 1409-1413 [PMID: 21720061 DOI: 10.2169/internalmedicine.504873]
143. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008; 103: 1944-1951 [PMID: 18564111 DOI: 10.1111/j.1572-0241.2008.01922.x]
144. Hino-Arinaga T, Ide T, Kuromatsu R, Miyajima I, Ogata K, Kuwahara R, Hisamochi A, Torimura T, Sata M. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol 2012; 47: 569-576 [PMID: 22187167 DOI: 10.1007/s00535-011-0519-2]
145. Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev 2014; 13: 435-440 [PMID: 24418295 DOI: 10.1016/j.autrev.2013.11.009]
146. Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008; 14: 3368-3373 [PMID: 18528934 DOI: 10.3748/wjg.14.3368]
147. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/ sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-553 [PMID: 11230733 DOI: 10.1053/jhep.2001.22131]
148. Levy C, Naik J, Giordano C, Mandalia A, O'Brien C, Bhamidimarri KR, Schiff ER, Martin P. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol 2014; 12: 1398-1405 [PMID: 24361417 DOI: 10.1016/j.cgh.2013.12.010]
149. Rojas CP, Bodicharla R, Campuzano-Zuluaga G, Hernandez L, Rodriguez MM. Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol 2014; 33: 202-209 [PMID: 24754367 DOI: 10.3109/15513815.2014.898721]
150. Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, Ziol M, Arrivé L, Beaugrand M, Poupon R, Valla D, Chazouillères O, Corpechot C. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009; 50: 528-537 [PMID: 19575454 DOI: 10.1002/hep.23024]
151. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385 [PMID: 21067838 DOI: 10.1016/j.jhep.2010.09.002]
152. Neuhauser M, Bjornsson E, Treeprasertsuk S, Enders F, Silveira M, Talwalkar J, Lindor K. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010; 105: 345-353 [PMID: 19888204 DOI: 10.1038/ajg.2009.616]
153. Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010; 8: 530-534 [PMID: 20304098 DOI: 10.1016/j.cgh.2010.03.004]
154. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosisautoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301 [PMID: 9695990 DOI: 10.1002/hep.510280203]
155. Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R, Menichella R, Ferri S, Cassani F, Bianchi FB, Lenzi M, Muratori L. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009; 104: 1420-1425 [PMID: 19491855 DOI: 10.1038/ajg.2009]
156. Coss Adame E, Granados J, Uribe M, Torre A. Does HLADR7 differentiate the overlap syndrome of auto-immune hepatitis-primary biliary cirrhosis (AIH-PBC) from those with auto-immune hepatitis type 1? Ann Hepatol 2011; 10: 28-32 [PMID: 21301006]
157. Lee H, Stapp RT, Ormsby AH, Shah VV. The usefulness of IgG and IgM immunostaining of periportal inflammatory cells (plasma cells and lymphocytes) for the distinction of autoimmune hepatitis and primary biliary cirrhosis and their staining pattern in autoimmune hepatitisprimary biliary cirrhosis overlap syndrome. Am J Clin Pathol 2010; 133: 430-437 [PMID: 20154281 DOI: 10.1309/AJCPE93GZSHUNTAI]
158. Abe K, Takahashi A, Nozawa Y, Imaizumi H, Hayashi M, Okai K, Kanno Y, Watanabe H, Ohira H. The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. Med Mol Morphol 2014; 47: 162-168 [PMID: 24969678 DOI: 10.1007/s00795-014-0082-z]
159. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366: 539-551 [PMID: 22316447 DOI: 10.1056/NEJMra1104650]
160. Umemura T, Zen Y, Hamano H, Ichijo T, Kawa S, Nakanuma Y, Kiyosawa K. IgG4 associated autoimmune hepatitis: a differential diagnosis for classical autoimmune hepatitis. Gut 2007; 56: 1471-1472 [PMID: 17504944 DOI: 10.1136/gut.2007.122283]
161. Paik WH, Ryu JK, Park JM, Song BJ, Park JK, Kim YT, Lee K. Clinical and pathological differences between serum immunoglobulin G4-positive and -negative type 1 autoimmune pancreatitis. World J Gastroenterol 2013; 19: 4031-4038 [PMID: 23840149 DOI: 10.3748/wjg.v19.i25.4031]
162. Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, Topazian MD, Clain JE, Pearson RK, Petersen BT, Vege SS, Lindor K, Farnell MB. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-715 [PMID: 18222442 DOI: 10.1053/j.gastro.2007.12.009]
163. Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int 2010; 30: 222-231 [PMID: 19650840 DOI: 10.1111/j.1478-3231.2009.02092.x]
164. Umemura T, Zen Y, Hamano H, Joshita S, Ichijo T, Yoshizawa K, Kiyosawa K, Ota M, Kawa S, Nakanuma Y, Tanaka E. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol 2011; 46 Suppl 1: 48-55 [PMID: 20862498 DOI: 10.1007/s00535-010-0323-4]
165. Trivedi PJ, Hirschfield GM. Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther 2012; 36: 517-533 [PMID: 22817525 DOI: 10.1111/j.1365-2036.2012.05223.x]
166. Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F, Volta U, Ferri A, Lenzi M, Bianchi FB. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006; 59: 280-284 [PMID: 16505279 DOI: 10.1136/jcp.2005.027367]
167. Liaskos C, Bogdanos DP, Davies ET, Dalekos GN. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol 2007; 60: 107-108 [PMID: 17213359 DOI: 10.1136/jcp.2006.039404]
168. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, Muratori L, Lenzi M, Bianchi G, Zauli D, Bianchi FB. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561-566 [PMID: 9303483 DOI: 10.1002/hep.510260305]
169. Czaja AJ . Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999; 30: 394-401 [PMID: 10190720 DOI: 10.1016/S0168-8278(99)80096-8]
170. Dbouk N, Parekh S. Impact of pretransplant antinuclear antibody and antismooth muscle antibody titers on disease recurrence and graft survival following liver transplantation in autoimmune hepatitis patients. J Gastroenterol Hepatol 2013; 28: 537-542 [PMID: 22432792 DOI: 10.1111/j.1440-1746.2012.07125.x]
171. Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Büschenfelde KH, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-1515 [PMID: 10801173 DOI: 10.1016/S0140-6736(00)02166-8]
172. Herkel J, Heidrich B, Nieraad N, Wies I, Rother M, Lohse AW. Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology 2002; 35: 403-408 [PMID: 11826415 DOI: 10.1053/jhep.2002.30699]
173. Kanzler S, Weidemann C, Gerken G, Löhr HF, Galle PR, Meyer zum Büschenfelde KH, Lohse AW. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31: 635-640 [PMID: 10551386 DOI: 10.1016/S0168-8278(99)80342-0]
174. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33: 208-215 [PMID: 10952238 DOI: 10.1016/S0168-8278(00)80361-X]
175. Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, Porta G, Nishioka M, Simon T, Daehnrich C, Schlumberger W, Galle PR, Lohse AW. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-264 [PMID: 12117891 DOI: 10.1136/gut.51.2.259]
176. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Dürr R, Mieli-Vergani G, Vergani D. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-664 [PMID: 11870381 DOI: 10.1053/jhep.2002.32092]
177. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-419 [PMID: 11866281 DOI: 10.1111/j.1572-0241.2002.05479.x]
178. Efe C, Ozaslan E, Wahlin S, Purnak T, Muratori L, Quarneti C, Yüksel O, Muratori P. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int 2013; 33: 190-196 [PMID: 23295051 DOI: 10.1111/liv.12022]
179. Zhang WC, Zhao FR, Chen J, Chen WX. Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/ liver pancreas in autoimmune hepatitis. PLoS One 2014; 9: e92267 [PMID: 24651126 DOI: 10.1371/journal.pone.0092267]
180. Czaja AJ . Autoantibody-negative autoimmune hepatitis. Dig Dis Sci 2012; 57: 610-624 [PMID: 22187100 DOI: 10.1007/s10620-011-2017-z]
181. Yuan J, Palioura S, Salazar JC, Su D, O'Donoghue P, Hohn MJ, Cardoso AM, Whitman WB, Söll D. RNA-dependent conversion of phosphoserine forms selenocysteine in eukaryotes and archaea. Proc Natl Acad Sci USA 2006; 103: 18923-18927 [PMID: 17142313 DOI: 10.1073/pnas.0609703104]
182. Palioura S, Sherrer RL, Steitz TA, Söll D, Simonovic M. The human SepSecS-tRNASec complex reveals the mechanism of selenocysteine formation. Science 2009; 325: 321-325 [PMID: 19608919 DOI: 10.1126/science.1173755]
183. Liaskos C, Bogdanos DP, Rigopoulou EI, Norman GL, Shurns Z, Al-Chalabi T, Krawitt EL, Mieli-Vergani G, Czaja AJ, Vergani D, Dalekos GN. Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis. J Hepatol 2007; 46 (Suppl 1): S250 (abstract) [DOI: 10.1016/S0168-8278(07)62258-2]
184. Eyraud V, Chazouilleres O, Ballot E, Corpechot C, Poupon R, Johanet C. Significance of antibodies to soluble liver antigen/ liver pancreas: a large French study. Liver Int 2009; 29: 857-864 [PMID: 19302185 DOI: 10.1111/j.1478-3231.2009.01986.x]
185. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012; 32: 85-92 [PMID: 21745277 DOI: 10.1111/j.1478-3231.2011.02502.x]
186. Zachou K, Gampeta S, Gatselis NK, Oikonomou K, Goulis J, Manoussakis MN, Renaudineau Y, Bogdanos DP, Dalekos GN. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. Liver Int 2014; Epub ahead of print [PMID: 25113420 DOI: 10.1111/liv.12658]
187. Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000; 95: 3238-3241 [PMID: 11095348 DOI: 10.1111/j.1572-0241.2000.03207.x]
188. Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP, Reinert P, Bernard O. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004; 2: 825-830 [PMID: 15354284 DOI: 10.1016/S1542-3565(04)00354-4]
189. Yamamoto AM, Cresteil D, Boniface O, Clerc FF, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993; 23: 1105-1111 [PMID: 7682958 DOI: 10.1002/eji.1830230519]
190. Klein R, Zanger UM, Berg T, Hopf U, Berg PA. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. Clin Exp Immunol 1999; 118: 290-297 [PMID: 10540193 DOI: 10.1046/j.1365-2249.1999.01027.x]
191. Duclos-Vallée JC, Hajoui O, Yamamoto AM, Jacz-Aigrain E, Alvarez F. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology 1995; 108: 470-476 [PMID: 7530671 DOI: 10.1016/0016-5085(95)90076-4]
192. Muratori L, Lenzi M, Ma Y, Cataleta M, Mieli-Vergani G, Vergani D, Bianchi FB. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995; 37: 406-412 [PMID: 7590439 DOI: 10.1136/gut.37.3.406]
193. Dalekos GN, Makri E, Loges S, Obermayer-Straub P, Zachou K, Tsikrikas T, Schmidt E, Papadamou G, Manns MP. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol 2002; 14: 35-42 [PMID: 11782573]
194. Gatselis NK, Georgiadou SP, Koukoulis GK, Tassopoulos N, Zachou K, Liaskos C, Hatzakis A, Dalekos GN. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther 2006; 24: 1563-1573 [PMID: 17094775 DOI: 10.1111/j.1365-2036.2006.03165.x]
195. Ferri S, Muratori L, Quarneti C, Muratori P, Menichella R, Pappas G, Granito A, Ballardini G, Bianchi FB, Lenzi M. Clinical features and effect of antiviral therapy on antiliver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol 2009; 50: 1093-1101 [PMID: 19398235 DOI: 10.1016/j.jhep.2009.02.020]
196. Sugimura T, Obermayer-Straub P, Kayser A, Braun S, Loges S, Alex B, Lüttig B, Johnson EF, Manns MP, Strassburg CP. A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens. Autoimmunity 2002; 35: 501-513 [PMID: 12765476 DOI: 10.1080/0891693021000069556]
197. Dalekos GN, Obermayer-Straub P, Bartels M, Maeda T, Kayser A, Braun S, Loges S, Schmidt E, Gershwin ME, Manns MP. Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. J Hepatol 2003; 39: 800-806 [PMID: 14568264 DOI: 10.1016/S0168-8278(03)00356-8]
198. Ma Y, Peakman M, Lobo-Yeo A, Wen L, Lenzi M, Gäken J, Farzaneh F, Mieli-Vergani G, Bianchi FB, Vergani D. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clin Exp Immunol 1994; 97: 94-99 [PMID: 8033426 DOI: 10.1111/j.1365-2249.1994.tb06585.x]
199. Durazzo M, Philipp T, Van Pelt FN, Lüttig B, Borghesio E, Michel G, Schmidt E, Loges S, Rizzetto M, Manns MP. Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology 1995; 108: 455-462 [PMID: 7835588 DOI: 10.1016/0016-5085(95)90074-8]
200. Muratori P, Czaja AJ, Muratori L, Granito A, Guidi M, Ferri S, Volta U, Mantovani W, Pappas G, Cassani F, Lenzi M, Bianchi FB. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci 2007; 52: 179-184 [PMID: 17160474 DOI: 10.1007/s10620-006-9495-4]
201. Crivelli O, Lavarini C, Chiaberge E, Amoroso A, Farci P, Negro F, Rizzetto M. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol 1983; 54: 232-238 [PMID: 6352105]
202. Csepregi A, Nemesánszky E, Luettig B, Obermayer-Straub P, Manns MP. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol 2001; 96: 910-911 [PMID: 11280576 DOI: 10.1111/j.1572-0241.2001.03383.x]
203. Bachrich T, Thalhammer T, Jäger W, Haslmayer P, Alihodzic B, Bakos S, Hitchman E, Senderowicz AM, Penner E. Characterization of autoantibodies against uridinediphosphate glucuronosyltransferase in patients with inflammatory liver diseases. Hepatology 2001; 33: 1053-1059 [PMID: 11343231 DOI: 10.1053/jhep.2001.24101]
204. Abuaf N, Johanet C, Chretien P, Martini E, Soulier E, Laperche S, Homberg JC. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992; 16: 892-898 [PMID: 1398495 DOI: 10.1002/hep.1840160407]
205. Lenzi M, Manotti P, Muratori L, Cataleta M, Ballardini G, Cassani F, Bianchi FB. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995; 36: 749-754 [PMID: 7797126 DOI: 10.1136/gut.36.5.749]
206. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 721-726 [PMID: 9659171 DOI: 10.1136/gut.42.5.721]
207. Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 643-649 [PMID: 10029623 DOI: 10.1016/S0016-5085(99)70186-1]
208. Muratori L, Sztul E, Muratori P, Gao Y, Ripalti A, Ponti C, Lenzi M, Landini MP, Bianchi FB. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001; 34: 494-501 [PMID: 11526534]
209. Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH, De Virgiliis S, Manns MP. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1997; 82: 1353-1361 [PMID: 9141515 DOI: 10.1210/jcem.82.5.3913]
210. Clemente MG, Meloni A, Obermayer-Straub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998; 114: 324-328 [PMID: 9453493 DOI: 10.1016/S0016-5085(98)70484-6]
211. Gebre-Medhin G, Husebye ES, Gustafsson J, Winqvist O, Goksoyr A, Rorsman F, Kämpe O. Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. FEBS Lett 1997; 412: 439-445 [PMID: 9276443 DOI: 10.1016/S0014-5793(97)00797-7]
212. Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987; 64: 494-500 [PMID: 3818889 DOI: 10.1210/jcem-64-3-494]
213. Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, Dalekos GN. Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. Int J Infect Dis 2009; 13: e157-e160 [PMID: 19008139 DOI: 10.1016/j.ijid.2008.08.011]
214. Renaudineau Y, Dalekos GN, Guéguen P, Zachou K, Youinou P. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol 2008; 34: 321-325 [PMID: 18197482 DOI: 10.1007/s12016-007-8050-1]
215. Liaskos C, Rigopoulou E, Zachou K, Georgiadou S, Gatselis N, Papamihali R, Dalekos GN. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun 2005; 24: 251-260 [PMID: 15848048 DOI: 10.1016/j.jaut.2005.01.016]
216. Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, Zachou K, Rigopoulou EI, Dalekos GN. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol 2008; 28: 501-511 [PMID: 18551357 DOI: 10.1007/s10875-008-9211-6]
217. Chen M, Shirai M, Czaja AJ, Kurokohchi K, Arichi T, Arima K, Kodama T, Nishioka M. Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 483-489 [PMID: 9641645 DOI: 10.1111/j.1440-1746.1998.tb00673.x]
218. Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D, Shums Z, Burlingame R, Norman GL. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 2006; 39: 341-348 [PMID: 16891223 DOI: 10.1080/08916930600783348]
219. Fusconi M, Vannini A, Dall'Aglio AC, Pappas G, Cassani F, Ballardini G, Frisoni M, Grassi A, Bianchi FB, Zauli D. Anticyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005; 22: 951-955 [PMID: 16268969 DOI: 10.1111/j.1365-2036.2005.02686.x]
220. Hausdorf G, Roggenbuck D, Feist E, Büttner T, Jungblut PR, Conrad K, Berg C, Klein R. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA - revival of a disease-activity marker in autoimmune hepatitis. Clin Chim Acta 2009; 408: 19-24 [PMID: 19576873 DOI: 10.1016/j.cca.2009.06.035]
221. Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 2003; 48: 1658-1664 [PMID: 12924665 DOI: 10.1023/A:1024748714580]
222. Guéguen P, Dalekos G, Nousbaum JB, Zachou K, Putterman C, Youinou P, Renaudineau Y. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006; 26: 495-505 [PMID: 17001515 DOI: 10.1007/s10875-006-9045-z]
223. Oikonomou KG, Zachou K, Dalekos GN. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev 2011; 10: 389-396 [PMID: 21241830 DOI: 10.1016/j.autrev.2010.12.009]
224. Zachou K, Oikonomou K, Renaudineau Y, Chauveau A, Gatselis N, Youinou P, Dalekos GN. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment Pharmacol Ther 2012; 35: 116-125 [PMID: 22050113 DOI: 10.1111/j.1365-2036.2011.04908.x]
225. Czaja AJ, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Dig Dis Sci 2004; 49: 611-618 [PMID: 15185865 DOI: 10.1023/B:DDAS.0000026306.36511.c8]
226. Yiannaki EE, Zintzaras E, Analatos A, Theodoridou C, Dalekos GN, Germenis AE. Evaluation of a microspherebased flow cytometric assay for diagnosis of celiac disease. J Immunoassay Immunochem 2004; 25: 345-357 [PMID: 15552589 DOI: 10.1081/IAS-200033832]
227. Germenis AE, Yiannaki EE, Zachou K, Roka V, Barbanis S, Liaskos C, Adam K, Kapsoritakis AN, Potamianos S, Dalekos GN. Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. Clin Diagn Lab Immunol 2005; 12: 941-948 [PMID: 16085912 DOI: 10.1128/CDLI.12.8.941-948.2005]
228. Dalekos GN, Bogdanos DP, Neuberger J. Celiac diseaserelated autoantibodies in end-stage autoimmune liver diseases: what is the message? Liver Int 2008; 28: 426-428 [PMID: 18339068 DOI: 10.1111/j.1478-3231.2008.01708.x]
229. Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, Takahashi S. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2006; 21: 1448-1454 [PMID: 16911691 DOI: 10.1111/j.1440-1746.2006.04434.x]
230. Rigopoulou EI, Dalekos GN. Molecular diagnostics of primary biliary cirrhosis. Expert Opin Med Diagn 2008; 2: 621-634 [PMID: 23495774 DOI: 10.1517/17530059.2.6.621]
231. Liaskos C, Bogdanos DP, Rigopoulou EI, Dalekos GN. Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art of facts or an artifact? J Gastroenterol Hepatol 2007; 22: 454-455 [PMID: 17295788 DOI: 10.1111/j.1440-1746.2006.04751.x]
232. Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 1047-1053 [PMID: 18719506 DOI: 10.1097/MCG.0b013e3181587d18]
233. 'Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibodypositive autoimmune hepatitis. Hepatology 2008; 48: 550-556 [PMID: 18666262 DOI: 10.1002/hep.22380]
234. Dinani AM, Fischer SE, Mosko J, Guindi M, Hirschfield GM. Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 682-684 [PMID: 22366178 DOI: 10.1016/j.cgh.2012.02.010]
235. Muratori L, Muratori P, Zauli D, Grassi A, Pappas G, Rodrigo L, Cassani F, Lenzi M, Bianchi FB. Antilactoferrin antibodies in autoimmune liver disease. Clin Exp Immunol 2001; 124: 470-473 [PMID: 11472410 DOI: 10.1046/j.1365-2249.2001.01524.x]
236. Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Haba R, Watanabe S, Senda S, Masaki T. Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases. Can J Gastroenterol 2012; 26: 125-129 [PMID: 22408762]
237. Muratori P, Muratori L, Gershwin ME, Czaja AJ, Pappas G, MacCariello S, Granito A, Cassani F, Loria P, Lenzi M, Bianchi FB. 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol 2004; 135: 154-158 [PMID: 14678277 DOI: 10.1111/j.1365-2249.2004.02332.x]
238. Renaudineau Y, Croquefer S, Jousse S, Renaudineau E, Devauchelle V, Guéguen P, Hanrotel C, Gilburd B, Saraux A, Shoenfeld Y, Putterman C, Youinou P. Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum 2006; 54: 2523-2532 [PMID: 16868973 DOI: 10.1002/art.22015]
239. Renaudineau Y, Deocharan B, Jousse S, Renaudineau E, Putterman C, Youinou P. Anti-alpha-actinin antibodies: a new marker of lupus nephritis. Autoimmun Rev 2007; 6: 464-468 [PMID: 17643934 DOI: 10.1016/j.autrev.2007.02.001]
240. McFarlane BM, Sipos J, Gove CD, McFarlane IG, Williams R. Antibodies against the hepatic asialoglycoprotein receptor perfused in situ preferentially attach to periportal liver cells in the rat. Hepatology 1990; 11: 408-415 [PMID: 2312054 DOI: 10.1002/hep.1840110312]
241. Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Büschenfelde KH, Poralla T. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 1993; 19: 55-63 [PMID: 8301043 DOI: 10.1016/S0168-8278(05)80176-X]
242. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733-1740 [PMID: 8794787 DOI: 10.1007/BF02088738]
243. Yoshioka M, Mizuno M, Morisue Y, Shimada M, Hirai M, Nasu J, Okada H, Sakaguchi K, Yamamoto K, Tsuji T. Antiasialoglycoprotein receptor autoantibodies, detected by a capture-immunoassay, are associated with autoimmune liver diseases. Acta Med Okayama 2002; 56: 99-105 [PMID: 12002624]
244. Hilgard P, Schreiter T, Stockert RJ, Gerken G, Treichel U. Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis. Hepatology 2004; 39: 1398-1407 [PMID: 15122769 DOI: 10.1002/hep.20172]
245. Husa P, Chalupa P, Stroblová H, Husová L, Slesinger P, Zajíc J. Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients. Acta Virol 2001; 45: 7-11 [PMID: 11394582]
246. Björnsson E, Talwalkar J, Treeprasertsuk S, Neuhauser M, Lindor K. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011; 9: 57-63 [PMID: 20723617 DOI: 10.1016/j.cgh.2010.07.016]
247. Schiano TD, Fiel MI. To B(iopsy) or not to B(iopsy) .... Clin Gastroenterol Hepatol 2011; 9: 3-4 [PMID: 20951834 DOI: 10.1016/j.cgh.2010.09.027]
248. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004; 24: 322-329 [PMID: 15287855 DOI: 10.1111/j.1478-3231.2004.0924.x]
249. Dienes HP, Erberich H, Dries V, Schirmacher P, Lohse A. Autoimmune hepatitis and overlap syndromes. Clin Liver Dis 2002; 6: 349-362, vi [PMID: 12122860 DOI: 10.1016/S1089-3261(02)00007-7]
250. Benseler V, Warren A, Vo M, Holz LE, Tay SS, Le Couteur DG, Breen E, Allison AC, van Rooijen N, McGuffog C, Schlitt HJ, Bowen DG, McCaughan GW, Bertolino P. Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci USA 2011; 108: 16735-16740 [PMID: 21933957 DOI: 10.1073/pnas.1112251108]
251. Te HS, Koukoulis G, Ganger DR. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut 1997; 41: 269-271 [PMID: 9301510 DOI: 10.1136/gut.41.2.269]
252. Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol 2008; 43: 951-958 [PMID: 19107339 DOI: 10.1007/s00535-008-2254-x]
253. Guindi M . Histology of autoimmune hepatitis and its variants. Clin Liver Dis 2010; 14: 577-590 [PMID: 21055683 DOI: 10.1016/j.cld.2010.07.003]
254. Yasui S, Fujiwara K, Yonemitsu Y, Oda S, Nakano M, Yokosuka O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011; 46: 378-390 [PMID: 20821236 DOI: 10.1007/s00535-010-0316-3]